Gilead Sciences, Inc. (NASDAQ:GILD) CFO Robin L. Washington sold 51,820 shares of the stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $85.00, for a total value of $4,404,700.00. Following the sale, the chief financial officer now owns 43,352 shares of the company’s stock, valued at $3,684,920. The sale was disclosed in a filing with the SEC, which is available through the SEC website.
Gilead Sciences, Inc. (NASDAQ:GILD) traded down 0.68% during trading on Monday, hitting $84.52. The stock had a trading volume of 10,125,177 shares. The firm has a market cap of $110.38 billion, a PE ratio of 9.18 and a beta of 1.19. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $86.27. The company’s 50 day moving average is $75.90 and its 200 day moving average is $69.72.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.11 by $0.45. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The firm had revenue of $7.14 billion for the quarter, compared to the consensus estimate of $6.35 billion. During the same period in the prior year, the firm earned $3.08 EPS. The firm’s revenue was down 8.2% on a year-over-year basis. Equities research analysts forecast that Gilead Sciences, Inc. will post $8.74 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, September 28th. Investors of record on Friday, September 15th will be given a $0.52 dividend. This represents a $2.08 annualized dividend and a dividend yield of 2.46%. The ex-dividend date of this dividend is Thursday, September 14th. Gilead Sciences’s payout ratio is 22.58%.
Several equities research analysts recently weighed in on GILD shares. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a report on Monday, August 28th. Vetr upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $89.27 target price for the company in a report on Wednesday, September 6th. Maxim Group restated a “hold” rating on shares of Gilead Sciences in a report on Thursday, July 27th. BMO Capital Markets restated an “outperform” rating and set a $82.00 target price (up from $72.00) on shares of Gilead Sciences in a report on Thursday, July 27th. Finally, Zacks Investment Research cut Gilead Sciences from a “buy” rating to a “hold” rating in a report on Tuesday, July 18th. Eleven research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $83.06.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. increased its position in shares of Gilead Sciences by 1.9% in the 2nd quarter. BlackRock Inc. now owns 104,906,494 shares of the biopharmaceutical company’s stock valued at $7,425,281,000 after acquiring an additional 1,937,031 shares during the period. Vanguard Group Inc. grew its position in Gilead Sciences by 2.4% during the 2nd quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock worth $6,571,355,000 after purchasing an additional 2,148,697 shares during the period. Bank of New York Mellon Corp grew its position in Gilead Sciences by 1.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 30,881,405 shares of the biopharmaceutical company’s stock worth $2,185,784,000 after purchasing an additional 310,607 shares during the period. FMR LLC grew its position in Gilead Sciences by 1.1% during the 2nd quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock worth $1,630,581,000 after purchasing an additional 258,005 shares during the period. Finally, Parnassus Investments CA grew its position in Gilead Sciences by 37.4% during the 1st quarter. Parnassus Investments CA now owns 16,726,150 shares of the biopharmaceutical company’s stock worth $1,110,228,000 after purchasing an additional 4,556,901 shares during the period. 74.05% of the stock is currently owned by hedge funds and other institutional investors.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.